PPARGC1A and glucose measurement: Translating antagonism to therapy, Tsuneki et al. (2016) administered the dual orexin receptor antagonist suvorexant during the rest phase in db/db type 2 diabetic mice and observed marked improvement in glucose tolerance, driven by downregulation of hepatic PEPCK and PGC-1α, reduced triglyceride accumulation, and lowered TNF-α expression.